Want to see AU:ATH full AI Analyst Report?
Top Page
Alterity Therapeutics
(Sydney:ATH)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.37
â–Ľ(-27.65% Downside)
Action:Reiterated
Date:10/03/26
The score is held down primarily by weak financial performance (ongoing losses, cash burn, and the latest period’s revenue at zero). Technicals also contribute negatively, with the stock trading below key moving averages and weak momentum indicators. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Low Leverage
Extremely low leverage reduces financial risk and preserves flexibility while Alterity funds development. A less debt-dependent capital structure can help management direct available resources toward clinical programs and absorb operating losses without the added burden of substantial interest or refinancing obligations.
Negative Factors
No Current Product Revenue
Zero recent revenue confirms that Alterity has not yet established a commercial earnings base. Until a candidate is approved and monetized, the company remains dependent on development progress and external funding, leaving future operating performance highly contingent on clinical and regulatory outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Extremely low leverage reduces financial risk and preserves flexibility while Alterity funds development. A less debt-dependent capital structure can help management direct available resources toward clinical programs and absorb operating losses without the added burden of substantial interest or refinancing obligations.
Read all positive factors
Alterity Therapeutics (ATH) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$61.87M
Dividend YieldN/A
Average Volume (3M)372.51K
Price to Earnings (P/E)―
Beta (1Y)1.72
Revenue GrowthN/A
EPS Growth-16.21%
CountryAU
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding229,150,850
10 Day Avg. Volume632,035
30 Day Avg. Volume372,514
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)2.83
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.95Price Target Upside86.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.03
Revenue Forecast (FY)AU$1.80M
Alterity Therapeutics Business Overview & Revenue Model
Company Description
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The c...
How the Company Makes Money
Alterity Therapeutics does not primarily generate revenue from product sales because it is a clinical-stage drug developer and, to the extent publicly available information indicates, it does not have an approved, commercialized therapy. Its fundi...
Alterity Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 5.44M | 4.02M | 3.92M | 5.12M |
| Gross Profit | -115.54K | 5.31M | 3.80M | 3.63M | 4.76M |
| EBITDA | -28.30M | -14.52M | -19.46M | -17.51M | -17.39M |
| Net Income | -23.40M | -12.15M | -19.12M | -13.81M | -12.85M |
Balance Sheet | |||||
| Total Assets | 46.02M | 46.03M | 19.22M | 27.32M | 41.36M |
| Cash, Cash Equivalents and Short-Term Investments | 37.32M | 40.66M | 12.64M | 15.77M | 34.81M |
| Total Debt | 193.47K | 155.46K | 159.04K | 210.38K | 117.49K |
| Total Liabilities | 3.29M | 3.62M | 5.43M | 4.50M | 5.89M |
| Stockholders Equity | 42.72M | 42.40M | 13.80M | 22.81M | 35.47M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -11.45M | -12.61M | -20.04M | -12.43M |
| Operating Cash Flow | -22.52M | -11.45M | -12.61M | -20.04M | -12.34M |
| Investing Cash Flow | 7.50M | -7.50M | -5.72K | -36.46K | -89.15K |
| Financing Cash Flow | 19.13M | 39.67M | 9.22M | 124.34K | 16.30M |
Alterity Therapeutics Risk Analysis
Alterity Therapeutics disclosed 44 risk factors in its most recent earnings report. Alterity Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Alterity Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$2.49B | 121.92 | 6.03% | 0.76% | -68.00% | -86.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$61.87M | -2.31 | -48.25% | ― | ― | -16.21% | |
44 Neutral | AU$166.59M | -9.79 | -103.42% | ― | ― | 5.88% | |
43 Neutral | AU$53.93M | -13.91 | -63.60% | ― | ― | 29.55% | |
42 Neutral | AU$3.35M | -0.28 | -617.89% | ― | ― | 13.67% | |
40 Underperform | AU$20.28M | -5.71 | -132.20% | ― | ― | -200.00% |
* Healthcare Sector Average
AU:ATH
Alterity Therapeutics
0.27
-0.29
-51.82%
AU:ACW
Actinogen Medical
0.05
0.01
34.29%
AU:CYP
Cynata Therapeutics Limited
0.01
-0.24
-95.65%
AU:ENP
Tryptamine Therapeutics
0.03
>-0.01
-11.11%
AU:1AI
Living Cell Technologies
0.01
0.00
0.00%
AU:NEU
Neuren Pharmaceuticals Limited
19.81
-0.98
-4.70%
Alterity Therapeutics Corporate Events
Alterity Therapeutics Sets 2026 AGM Date and Director Nomination Deadline
Sep 25, 2026
Alterity Therapeutics has scheduled its next Annual General Meeting for 11:00 a.m. AEDT on 20 November 2026, with full meeting details to be circulated to shareholders in a forthcoming Notice of Meeting and posted on the ASX announcements platform...
Alterity Flags Development Risks Around Lead Neurodegeneration Drug ATH434
Sep 23, 2026
Alterity Therapeutics has issued a corporate presentation outlining the key risks and assumptions underpinning its development programs, particularly for its lead drug candidate ATH434. The company highlights that its operations depend heavily on ...
Alterity Therapeutics to Spotlight MSA Program at ASX SMIDcaps Conference
Sep 17, 2026
Alterity Therapeutics, a clinical-stage biotechnology company, develops disease-modifying therapies for neurodegenerative conditions with a focus on Multiple System Atrophy and related Parkinsonian disorders. Its lead drug candidate, ATH434, has d...
Alterity Therapeutics Seeks Quotation for New ASX Shares
Sep 16, 2026
Alterity Therapeutics has applied for quotation of 50,000 new ordinary fully paid shares on the ASX, with an issue date of Sept. 16, 2026. The modest size of the issuance suggests a routine capital management move, potentially related to the exerc...
Alterity Therapeutics Issues 8.4 Million Shares Under Underwriting Deal
Sep 8, 2026
Alterity Therapeutics Limited, an ASX-listed Australian biopharmaceutical company, has issued 8,400,000 fully paid ordinary shares to MST Financial Services and sub-underwriters under a previously announced underwriting agreement tied to its ATHO ...
Alterity Therapeutics Seeks ASX Quotation for 8.4 Million New Shares
Sep 8, 2026
Alterity Therapeutics Limited has applied for quotation of 8,400,000 new ordinary fully paid shares on the Australian Securities Exchange. The securities fall under exception 10 of ASX Listing Rule 7.2, indicating the issue is within the exchange&...
Alterity Therapeutics to Spotlight MSA Program at Cantor Global Healthcare Conference
Sep 2, 2026
Alterity Therapeutics, a clinical-stage biotechnology company developing disease-modifying treatments for Multiple System Atrophy and related Parkinsonian disorders, is progressing its lead asset ATH434 following encouraging Phase 2 clinical resul...
Alterity Therapeutics Updates Director Equity Holdings After Option Expiry
Sep 2, 2026
Alterity Therapeutics has reported a change in the securities interests of director David Stamler, detailing adjustments to his holdings in ordinary shares, options and American Depositary Shares. The filing confirms that a tranche of listed optio...
Alterity Director Peter Marks Converts Options, Lifts Equity Stake
Sep 2, 2026
Alterity Therapeutics has disclosed a change in director Peter Marks’ interests in the company’s securities, lodged with the ASX under listing rule requirements. The filing shows Marks, through Lampam Pty Ltd, converted 47,620 listed o...
Alterity Therapeutics Seeks ASX Quotation for New Ordinary Shares
Sep 1, 2026
Alterity Therapeutics has applied to the ASX for quotation of 485,489 new ordinary fully paid shares, following the issue of these securities on August 31, 2026. The additional quoted shares, arising from the exercise or conversion of existing opt...
Alterity Therapeutics Files 2026 Annual Report and XBRL Data with SEC
Aug 31, 2026
Alterity Therapeutics has filed its Annual Report on Form 20-F, including audited consolidated financial statements for the year ended June 30, 2026, with the U.S. Securities and Exchange Commission. The company also submitted XBRL interactive dat...
Alterity Taps Underwritten ATHO Options to Fund ATH434 MSA Program
Aug 31, 2026
Alterity Therapeutics has entered into an underwriting agreement with MST Financial Services to support the exercise of up to 8.4 million ATHO listed options ahead of their expiry on 31 August 2026. The arrangement is designed to secure funding fo...
Alterity Therapeutics Seeks ASX Quotation for 1.7 Million New Shares
Aug 28, 2026
Alterity Therapeutics has applied for quotation of 1,714,936 new ordinary fully paid shares on the Australian Securities Exchange. The new securities, issued on 28 August 2026, modestly increase the company’s listed share capital and provide...
Alterity Therapeutics Files Updated Corporate Governance Statement with ASX
Aug 28, 2026
Alterity Therapeutics has lodged its updated corporate governance statement for the year ended 30 June 2026, confirming it is available on the company’s website and has been approved by the board as of 28 August 2026. The filing, made via Ap...
Alterity Therapeutics Doubles Annual Loss as It Ramps Up Neurodegeneration R&D
Aug 28, 2026
Alterity Therapeutics reported a sharp increase in interest income to A$1.72 million for the year ended 30 June 2026, but its net loss nearly doubled to A$23.4 million as it continued to invest in its neurodegenerative disease pipeline. The compan...
Alterity Therapeutics seeks ASX quotation for new ordinary shares
Aug 21, 2026
Alterity Therapeutics has applied for quotation on the ASX of 169,977 new fully paid ordinary shares. The securities, issued on 21 August 2026 following the exercise or conversion of existing options or other convertible instruments, modestly expa...
Alterity Discloses Regal Funds’ Derivative Positions Under Takeovers Panel Guidance
Aug 17, 2026
Alterity Therapeutics has disclosed that it received a notice from Regal Funds Management Asia, acting for the Amazon Market Neutral Fund and Zambezi Absolute Return Fund, regarding long equity derivative positions in the company. The disclosure, ...
Alterity Therapeutics Expands Equity Base With New ASX Share Quotation
Aug 10, 2026
Alterity Therapeutics Limited has applied for the quotation of 204,306 new ordinary fully paid shares on the ASX, with an issue date of August 10, 2026. The securities arise from the exercise of options or conversion of other instruments, modestly...
Alterity Therapeutics to Highlight MSA Program at Canaccord Growth Conference
Aug 6, 2026
Alterity Therapeutics will showcase its neurodegenerative disease pipeline at the 46th Annual Canaccord Genuity Growth Conference, where CEO David Stamler is scheduled to present to U.S. growth investors on August 11, 2026. The presentation will b...
Alterity Therapeutics Adds 81,838 New Shares to ASX Listing
Aug 3, 2026
Alterity Therapeutics Limited has applied for quotation on the ASX of 81,838 new ordinary fully paid shares, signalling a modest expansion of its listed equity base. The additional securities arise from the exercise or conversion of existing optio...
Alterity Wins FDA Backing for ATH434 Phase 3 Pathway in Multiple System Atrophy
Jul 30, 2026
Alterity Therapeutics, listed in Australia and the U.S., develops disease-modifying therapies for neurodegenerative conditions, with lead candidate ATH434 aimed at Multiple System Atrophy, a rare disorder lacking approved treatments. The company h...
Alterity Options Near Expiry as Company Flags Potential Capital Impact
Jul 28, 2026
Alterity Therapeutics has notified investors that 18,443,495 quoted options trading under ASX code ATHO will expire on 31 August 2026, with official quotation to cease on 25 August 2026. Each option is exercisable at $0.50 into one fully paid ordi...
Alterity Therapeutics Seeks ASX Quotation for New Share Issuance
Jul 28, 2026
Alterity Therapeutics Limited has applied for the quotation of 60,729 new ordinary fully paid shares on the ASX, issued on July 28, 2026. The additional securities arise from the exercise or conversion of existing options or other convertible inst...
Alterity Bolsters Cash Reserves with A$3.98m R&D Tax Refund
Jul 9, 2026
Alterity Therapeutics has secured a A$3.98 million research and development tax refund from the Australian Government for the 2025 financial year, including interest, under the country’s RD tax incentive scheme. The refundable offset support...
Alterity Therapeutics Seeks ASX Quotation for New Ordinary Shares
Jul 9, 2026
Alterity Therapeutics has applied to the Australian Securities Exchange for quotation of 76,191 new ordinary fully paid shares. The new securities result from the exercise or conversion of existing options or other convertible instruments, modestl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.